Cyclodextrins-Phospholipids Complex Loaded Nanofibers for Improved Oral Bioavailability and Brain Targeting for...

Depression and anxiety have emerged as significant public health concerns worldwide, with conventional pharmacotherapy often limited by poor solubility, low bioavailability, and suboptimal brain targeting of therapeutic agents. To address these challenges, this study proposes a novel drug delivery system integrating cyclodextrin-phospholipid inclusion complexes with electrospun nanofiber technology. The primary objective is to enhance drug solubility, permeability, and sustained release, thereby improving brain uptake and therapeutic efficacy of antidepressant and anxiolytic drugs. In this multicomponent approach, the selected drug is initially encapsulated within a cyclodextrin- phospholipid cavity, forming a supramolecular inclusion complex that improves solubility and membrane permeability of otherwise insoluble drugs. These complexes are then incorporated into a nanofiber matrix via electrospinning, resulting in a high-surface-area scaffold that allows for increased drug loading and controlled release. By combining the advantages of cyclodextrin complexation, phospholipid-based delivery, and electrospun nanofiber technology, this platform offers a synergistic solution to overcome existing limitations in neuropsychiatric drug delivery. The porous structure of the nanofibers facilitates higher drug entrapment and sustained release, potentially reducing dosing frequency and improving patient compliance. This innovative approach can be validated using various preclinical models. Overall, it represents a promising alternative for managing depression and anxiety, with the potential to transform therapeutic strategies.